Other Events ·
Cullinan Therapeutics reports velinotamig data: 8 of 9 patients achieve meaningful SLE reduction
CGEMCullinan Therapeutics, Inc.
Cullinan Therapeutics announced interim clinical data from its ongoing Phase 1b/2a trial of velinotamig in patients with active, refractory systemic lupus erythematosus (SLE). Among the first nine evaluable patients with at least four weeks of follow-up, eight achieved a clinically meaningful reduction of at least four points in SLEDAI-2K disease activity scores. In renal assessments, five of seven patients with high baseline proteinuria experienced marked reductions, and four achieved complete renal responses within 24 weeks. The drug demonstrated a favorable safety profile with no dose-limiting toxicities or severe cytokine release syndrome. Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing T cell engagers for autoimmune diseases and cancer.